Orthopedic Biomaterials Market Report Suite - Australia - 2020-2026

Throughout this medical market research, the publisher analyzed 48 orthobiologics companies in Australia and utilized their comprehensive methodology to understand the Market Sizes, Unit Sales, ASPs, Company Market Shares, and to create accurate forecasts.

While this MedSuite report contains all of the Australian Orthopedic Biomaterials market analysis, each of the market segments is also available as stand-alone MedCore reports. Additionally, this research includes an orthobiologics procedure volume analysis which can also be purchased as a separate report, MedPro.

Markets Covered

Procedure Volumes for the Australian Orthopedic Biomaterials Devices – MedPro
Orthopedic Bone Graft Substitute Market - MedCore
Orthopedic Growth Factor Market - MedCore
Hyaluronic Acid Viscosupplementation Market - MedCore

Australian Orthopedic Biomaterials Market Insights

With some exceptions, tissue supply for allografts and DBM allografts is constrained by the number of available donors. Furthermore, allografts are primarily sold by bone banks in Australia, which is attributed to a relatively high barrier to entry to the market for international companies.

Surgical procedures that require the use of orthopedic biomaterials are generally associated with diseases and indications that become more prevalent in the population with an increase in age, such as osteoarthritis of the spine and knee. In 2019, over 15% of Australians were aged 65 and over; this proportion is projected to grow steadily over the forecast period, as further cohorts of baby boomers turn 65.

Overall, the Australia orthopedic biomaterials market was valued at $63.8 million in 2019. This is expected to increase over the forecast period at a CAGR of 4.9% to reach $89.4 million.

LIST OF FIGURESLIST OF CHARTSEXECUTIVE SUMMARYAUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEWCOMPETITIVE ANALYSISMARKET TRENDSMARKET DEVELOPMENTSPROCEDURE NUMBERSMARKETS INCLUDEDKEY REPORT UPDATESVERSION HISTORY

RESEARCH METHODOLOGY

Step 1: Project Initiation & Team Selection
Step 2: Prepare Data Systems and Perform Secondary Research
Step 3: Preparation for Interviews & Questionnaire Design
Step 4: Performing Primary Research
Step 5: Research Analysis: Establishing Baseline Estimates
Step 6: Market Forecast and Analysis
Step 7: Identify Strategic Opportunities
Step 8: Final Review and Market Release
Step 9: Customer Feedback and Market Monitoring

PRODUCT ASSESSMENT

2.1 INTRODUCTION
2.2 PRODUCT PORTFOLIOS
2.2.1 Bone Graft Substitutes
2.2.2 Growth Factors
2.2.2.1 Other products
2.2.3 Hyaluronic Acid Viscosupplementation (HAV)
2.3 REGULATORY ISSUES AND RECALLS
2.3.1 Bone Graft Substitutes
2.3.1.1 Allografts
2.3.1.1.1 MTF
2.3.1.2 DBM
2.3.1.2.1 AlloSource
2.3.1.2.2 SeaSpine
2.3.1.2.3 RTI Surgical
2.3.1.3 Synthetics
2.3.1.3.1 Abyrx
2.3.1.3.2 Zimmer Biomet
2.3.2 Growth Factors
2.3.2.1.1 Medtronic
2.3.3 Hyaluronic Acid Viscosupplementation
2.3.3.1 Three-injection
2.3.3.1.1 Ferring Pharmaceuticals
2.4 CLINICAL TRIALS
2.4.1 Bone Graft Substitutes
2.4.1.1 Allografts
2.4.1.1.1 Providence Medical Technology
2.4.1.1.2 The University of Texas Health Science
2.4.1.1.3 University of Winchester
2.4.1.2 BDM
2.4.1.2.1 K2M
2.4.1.2.2 Zimmer Biomet
2.4.1.3 Synthetics
2.4.1.3.1 Baxter
2.4.1.3.2 Bonesupport
2.4.1.3.3 DePuy Synthes
2.4.1.3.4 NuVasive
2.4.1.3.5 RTI surgical
2.4.1.3.6 Sunstar GUIDOR
2.4.1.4 Other materials and comparison
2.4.1.4.1 Seoul National University Hospital.
2.4.1.4.2 Sewon Cellontech
2.4.1.4.3 SurgaColl Technologies Limited
2.4.1.4.4 University of Colorado
2.4.1.4.5 University of Padova
2.4.2 Growth Factors
2.4.2.1.1 Bioventus
2.4.2.1.2 Cerapedics
2.4.2.1.3 CGBio
2.4.2.1.4 Isto
2.4.2.1.5 Medtronic
2.4.2.1.6 NuVasive
2.4.2.1.7 Wright
2.4.2.1.8 Others
2.4.3 Hyaluronic Acid Viscosupplementation
2.4.3.1.1 Anika Therapeutics
2.4.3.1.2 Bioventus
2.4.3.1.3 Cario University
2.4.3.1.4 Ferring Pharmaceuticals
2.4.3.1.5 Federal University of Minas Gerais
2.4.3.1.6 Fidia Pharma USA Inc.
2.4.3.1.7 Istituto Ortopedico Rizzoli
2.4.3.1.8 University Hospital
2.4.3.1.9 Universidade Nova de Lisboa

AUSTRALIAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW

3.1 INTRODUCTION
3.1.1 Bone Graft Substitutes
3.1.2 Growth Factors
3.1.3 Hyaluronic Acid (HA) Viscosupplementation
3.2 CURRENCY EXCHANGE RATE
3.3 MARKET OVERVIEW AND TREND ANALYSIS
3.4 DRIVERS AND LIMITERS
3.4.1 Market Drivers
3.4.2 Market Limiters
3.5 COMPETITIVE MARKET SHARE ANALYSIS
3.6 MERGERS AND ACQUISITIONS
3.7 COMPANY PROFILES
3.7.1 Anika Therapeutics
3.7.2 Bioventus
3.7.3 DePuy Synthes
3.7.4 Ferring Pharmaceuticals
3.7.5 Fidia Pharmaceuticals
3.7.6 Genzyme (Sanofi Group)
3.7.7 Harvest Technologies (Terumo BCT)
3.7.8 Integra LifeSciences
3.7.9 Medtronic
3.7.10 Musculoskeletal Transplant Foundation (MTF)
3.7.11 NuVasive
3.7.12 Orthofix
3.7.13 RTI Surgical
3.7.14 Stryker
3.7.15 Vericel Corporation (formerly Aastrom Bioscience)
3.7.16 Zimmer Biomet
3.8 SWOT ANALYSIS
3.8.1 Anika Therapeutics
3.8.2 Bioventus
3.8.3 DePuy Synthes
3.8.4 Ferring Pharmaceuticals
3.8.5 Fidia Pharmaceuticals
3.8.7 Harvest Technologies (Terumo BCT)
3.8.8 Integra LifeSciences
3.8.9 Medtronic
3.8.10 Musculoskeletal Transplant Foundation (MTF)
3.8.11 NuVasive
3.8.12 Orthofix
3.8.14 Stryker
3.8.15 Vericel Corporation (formerly Aastrom Bioscience)
3.8.16 Zimmer Biomet

PROCEDURE NUMBERS

4.1 INTRODUCTION
4.2 PROCEDURES
4.2.1 Orthopedic Biomaterial Procedures by Segment
4.2.2 Orthopedic Bone Grafting Procedures
4.2.2.1 Units per Procedure by Indication
4.2.2.2 Orthopedic Bone Grafting Procedures by Material
4.2.2.2.1 Autograft Procedures by Indication
4.2.2.2.2 Allograft Procedures by Indication
4.2.2.2.3 DBM Allograft Procedures by Indication
4.2.2.2.4 Synthetic Procedures by Indication
4.2.2.3 Orthopedic Bone Grafting Procedures by Indication
4.2.3 Orthopedic Growth Factor Procedures
4.2.4 Hyaluronic Acid Supplementation Procedures
4.2.4.1 Hyaluronic Acid Supplementation Procedures by Injection Cycle

ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET

5.1 INTRODUCTION
5.2 MARKET OVERVIEW
5.2.1 Orthopedic Bone Graft Substitute Market by Material
5.2.2 Orthopedic Bone Graft Substitute Market by Indication
5.3 MARKET ANALYSIS AND FORECAST
5.3.1 Total Orthopedic Bone Graft Substitute Market
5.3.2 Orthopedic Bone Graft Substitute Market by Material
5.3.2.1 Allograft Bone Graft Substitute Market
5.3.2.1.1 Allograft Bone Graft Substitute Market by Indication
5.3.2.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Market
5.3.2.2.1 Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication
5.3.2.3 Synthetic Bone Graft Substitute Market
5.3.2.3.1 Synthetic Bone Graft Substitute Market by Indication
5.3.3 Orthopedic Bone Graft Substitute Market by Indication
5.3.3.1 Spine Bone Graft Substitute Market
5.3.3.2 Cervical Spine Bone Graft Substitute Market
5.3.3.3 Thoracolumbar Spine Bone Graft Substitute Market
5.3.3.4 Trauma Bone Graft Substitute Market
5.3.3.5 Non-Union Trauma Bone Graft Substitute Market
5.3.3.6 Fresh Fracture Trauma Bone Graft Substitute Market
5.3.3.7 Large Joint Reconstruction Bone Graft Substitute Market
5.3.3.8 Hip Reconstruction Bone Graft Substitute Market
5.3.3.9 Knee Reconstruction Bone Graft Substitute Market
5.3.3.10 Foot Reconstruction Bone Graft Substitute Market
5.3.3.11 Craniomaxillofacial Bone Graft Substitute Market
5.3.3.12 Oncology Bone Graft Substitute Market
5.4 DRIVERS AND LIMITERS
5.4.1 Market Drivers
5.4.2 Market Limiters
5.5 COMPETITIVE MARKET SHARE ANALYSIS

ORTHOPEDIC GROWTH FACTOR MARKET

6.1 INTRODUCTION
6.1.1 BMP-2 (Medtronic)
6.1.2 PDGF-BB (Wright Medical)
6.1.3 P-15 Synthetic Small Peptide (Cerapedics)
6.1.4 P-15 Synthetic Small Peptide (Biocomposites)
6.2 MARKET ANALYSIS AND FORECAST
6.3 DRIVERS AND LIMITERS
6.3.1 Market Drivers
6.3.2 Market Limiters
6.4 COMPETITIVE MARKET SHARE ANALYSIS

HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

7.1 INTRODUCTION
7.1.1 Benefits of Viscosupplementation
7.1.2 Synovial Fluid
7.2 MARKET OVERVIEW
7.3 MARKET ANALYSIS AND FORECAST
7.3.1 Total Hyaluronic Acid Viscosupplementation Market
7.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market
7.3.3 Three-Injection Hyaluronic Acid Viscosupplementation Market
7.4 DRIVERS AND LIMITERS
7.4.1 Market Drivers
7.4.2 Market Limiters
7.5 COMPETITIVE MARKET SHARE ANALYSIS

ABBREVIATIONS